课题基金 / 基金详情

EFFECT OF TROGLITAZONE ON CYP 3A4 & ON DEXAMETHASONE SUPPRESSION TEST

EFFECT OF TROGLITAZONE ON CYP 3A4 & ON DEXAMETHASONE SUPPRESSION TEST
曲格列酮对 CYP 3A4 的影响
批准号：
6303498
负责人：
CRAIG A JAFFE
金额：
$0.02万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2001-02-28
来源：
https://reporter.nih.gov/project-details/6303498
关键词：
clinical research clinical trials cytochrome P450 dexamethasone suppression test diabetes mellitus therapy drug adverse effect drug screening /evaluation enzyme activity human subject hypoglycemic agents troglitazone

项目摘要

项目成果

CRAIG A JAFFE的其他基金

相似基金

相关文献

中文摘要
翻译
我们最近发现了一名患者，他的小剂量地塞米松抑制试验(DST)假阳性，可能是由新的胰岛素增敏剂曲格列酮(瑞祖林)治疗引起的。来自临床研究的数据表明，曲格列酮诱导肝脏细胞色素P3A4，这是肝脏中最常见的药物代谢酶，也是地塞米松代谢的酶。我们建议，随着曲格列酮使用频率的提高和适应症的扩大，接受曲格列酮治疗的患者的假阳性DST将变得普遍。拟议的调查将确定曲格列酮是否确实通过增加CYP3A4活性来改变DST。
英文摘要
We have recently identified a patient who had a false positive low dose dexamethasone suppression test (DST) that likely resulted from treatment with a new insulin sensitizing agent, troglitazone (Rezulin). Data from clinical studies suggest that troglitazone induces hepatic CYP3A4, the most prevalent drug metabolizing enzyme in the liver and the enzyme that is also responsible for the metabolism of dexamethasone. We suggest that as troglitazone becomes more frequently used and as its indications for use broaden, false positive DST in patients treated with troglitazone will become common. The proposed investigations will establish whether troglitazone does alter DST via an increase in CYP3A4 activity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHYSIOLOGICAL IMPORTANCE OF GROWTH HORMONE PULSATILITY
PHYSIOLOGICAL IMPORTANCE OF GROWTH HORMONE PULSATILITY
PHYSIOLOGICAL IMPORTANCE OF GROWTH HORMONE PULSATILITY
Physiological Importance of Growth Hormone Pulsatility
海外基金